Qiagen, Inovio to develop NGS CDx

Create PDF

VGX-3100 is Inovio’s late-stage DNA immunotherapy candidate. It is currently in two phase three trials (REVEAL 1 and REVEAL 2), with the potential to become the first non-surgical treatment for advanced pre-cancerous cervical lesions associated with HPV-16 and HPV-18.

Inovio Pharmaceuticals, 267-440-4200
Qiagen, 800-426-8157